NEWS DETAIL

Lonza Expands Conjugation Facility with Two Additional Manufacturing Suites

Basel, Switzerland, 21 December 2020 – Lonza today announced an investment to further expand bioconjugation capabilities at its Visp (CH) site. The expansion adds two production suites to the existing conjugation facility providing development and manufacturing infrastructure for clinical and commercial supply. In addition, an extension to laboratory space will double the analytical and process development capacity. The new capacity is expected to be fully operational for customers from the first half of 2022.

The manufacturing extension spans approximately 1500m2 and adds 30% additional capacity for clinical and commercial supply. An additional support building of 5000m2 will provide space for logistics, storage and other supporting infrastructure to ensure an optimal workflow. This highly flexible setup will enable bioconjugation processes using single-use, stainless steel and hybrid concepts.

The bioconjugation capacity expansion complements Lonza's recent expansion of customer-specific suites as part of the Ibex® Dedicate model. In addition, expansions in payload manufacturing capacity and drug product sterile fill and finish will support the increasing development and manufacturing needs for bioconjugates. The continued investments into the Visp (CH) site provide a flexible solution for small, mid and large biopharmaceutical companies interested in scaling their bioconjugates and bringing them to market quickly and with reduced supply chain risks.

Since 2006, Lonza has produced over 600 cGMP batches of bioconjugated products for over 60 different projects. The company's experience in navigating the complex supply chain, developing commercial-scale conjugation and purification processes allows customers to streamline regulatory approvals and meet the growing market demands.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG. 

Lonza Contact Details

Dr. Sanna Fowler
Head of External Communications
Lonza Group Ltd
Tel 41 61 316 8929
[email protected]

Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel 41 79 421 1609
[email protected]

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.